Los Angeles—Researchers are poised for federal approval of treatment that could halt or prevent devastating vision loss from the most damaging form of age-related macular degeneration (ARMD), a development they describe as part of a therapeutic renaissance touched off by new photosensitizing agents.
"Photodynamic therapy is currently under review by the Food and Drug Administration [FDA], and we're hoping it will be approved for use in early 2000," said Joan W. Miller, MD, associate professor of ophthalmology at Harvard Medical School, during a seminar sponsored by Research to Prevent Blindness, a New York–based vision research foundation.
Voelker R. Vision Researchers Seek to Be Armed Against Damaging ARMD. JAMA. 1999;282(18):1711-1712. doi:10.1001/jama.282.18.1711-JMN1110-3-1